This is a working overview of chronic hepatitis B, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-23 and is reviewed periodically as new material appears.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
=== Canthaxanthin === Canthaxanthin is most commonly used as a color additive in certain foods. Although the FDA has approved the use of canthaxanthin in food, it does not approve its use as a tanning agent and has issued warnings concerning its use. When used as a color additive, only very small amounts of canthaxanthin are needed. As a tanning agent, however, much larger quantities are used. After canthaxanthin is consumed, it is deposited throughout the body, including in the layer of fat below the skin, which turns an orange-brown color. These types of tanning pills have been linked to various side effects, including hepatitis and canthaxanthin retinopathy, a condition in which yellow deposits form in the retina of the eye. Other side effects including damage to the digestive system and skin surface have also been noted.
Phillips acquired Experimental and Applied Sciences (EAS) from founders Anthony Almada and Ed Byrd in 1996. He promoted the company's products through heavy editorial-style advertisements in MM2K and, led by flagship products like Myoplex (a meal replacement powder), the creatine supplement Phosphagen, and HMB, he eventually rose to the forefront of the nutritional supplement industry, where he remained for more than five years. By 1995 Phillips was a multi-millionaire, and was well known in celebrity and sports circles. Athletes like José Canseco would contact Phillips for advice on steroids, and he also consulted with celebrities such as Jerry Seinfeld, John Elway, Sylvester Stallone and Demi Moore. In 1999, Phillips sold his majority interest in EAS (though he remained on the Board of Directors for a number of years afterward) to North Castle Partners for $160 million. Phillips retained about a third of the company, which he sold in 2004 and is no longer involved with EAS.
In regard to companies, the Court of Justice held in R (Daily Mail and General Trust plc) v HM Treasury that member states could restrict a company moving its seat of business, without infringing TFEU article 49. This meant the Daily Mail newspaper's parent company could not evade tax by shifting its residence to the Netherlands without first settling its tax bills in the UK. The UK did not need to justify its action, as rules on company seats were not yet harmonised. By contrast, in Centros Ltd v Erhversus-og Selkabssyrelsen the Court of Justice found that a UK limited company operating in Denmark could not be required to comply with Denmark's minimum share capital rules. UK law only required £1 of capital to start a company, while Denmark's legislature took the view companies should only be started up if they had 200,000 Danish krone (around €27,000) to protect creditors if the company failed and went insolvent. The Court of Justice held that Denmark's minimum capital law infringed Centros Ltd's freedom of establishment and could not be justified, because a company in the UK could admittedly provide services in Denmark without being established there, and there were less restrictive means of achieving the aim of creditor protection. This approach was criticised as potentially opening the EU to unjustified regulatory competition, and a race to the bottom in legal standards, like the US state of Delaware, which is argued to attract companies with the worst standards of accountability, and unreasonably low corporate tax.
=== Imaging === Radiography can be used to image a tumor and determine whether it is malignant. Smaller tumors are more likely benign. For example, regarding lung cancer, 80% of lung nodules less than 2 cm in diameter are benign. Most benign nodules are smoothed radiopaque densities with clear margins, but these are not exclusive signs of benign tumors.
== Diagnostic criteria == According to the WHO criteria as revised in 2000, a cardiac troponin rise accompanied by either typical symptoms, pathological Q waves, ST elevation or depression or coronary intervention are diagnostic of MI. Previous WHO criteria formulated in 1979 put less emphasis on cardiac biomarkers; according to these, a patient is diagnosed with myocardial infarction if two (probable) or three (definite) of the following criteria are satisfied:
Sources: en.wikipedia.org
=== Congregation for the Causes of Saints === On 8 May 1969, Pope Paul VI issued the apostolic constitution Sacra Rituum Congregatio, separating the Congregation into two parts: The Congregation for the Divine Worship and the renamed Sacred Congregation for the Causes of Saints, which was given three offices, those of the judiciary, the Promoter General of the Faith, and the historical-juridical. With the changes in the canonization process introduced by Pope John Paul II in 1983, a College of Relators, with five relators (priests appointed to oversee the canonisation process), was added to prepare the cases of those declared as Servants of God. In January 2014, the Prefect of the Congregation announced that at the direction of Pope Francis those working on canonizations must adhere to financial guidelines to eliminate unfairness in the treatment of cases based on the financial resources provided. According to L'Osservatore Romano, Pope Francis hoped to promote the causes of those less well-known, those from poorer regions, and those who were victims of 20th-century totalitarian persecutions.
== Cause == G6PD deficiency results from mutations in the G6PD gene. The G6PD gene contributes to the production of glucose-6-phosphate dehydrogenase. Chemical reactions involving glucose-6-phosphate dehydrogenase produce compounds that prevent reactive oxygen species from building up to toxic levels within red blood cells. If a reduction in the amount of glucose-6-phosphate dehydrogenase or alteration of structure occurs due to G6PD gene mutations, the enzyme loses its protective role, leading to the accumulation of reactive oxygen species and thus damaging red blood cells.
One of the first memorials was the Tribute in Light, an installation of 88 searchlights at the footprints of the World Trade Center towers. In New York City, the World Trade Center Site Memorial Competition was held to design an appropriate memorial on the site. The winning design, Reflecting Absence, was selected in August 2006, and consists of a pair of reflecting pools in the footprints of the towers, surrounded by a list of the victims' names in an underground memorial space. The memorial was completed on the 10th anniversary of the attacks in 2011; a museum also opened on site in May 2014. The Sphere by the German sculptor Fritz Koenig is the world's largest bronze sculpture of modern times, and stood between the Twin Towers on the Austin J. Tobin Plaza from 1971 until the attacks. The sculpture, weighing more than 20 tons, was the only remaining work of art to be recovered largely intact from the ruins of the towers. Since then, the work of art, known in the U.S. as The Sphere, has been transformed into a symbolic monument of 9/11 commemoration. After being dismantled and stored near a hangar at John F. Kennedy International Airport, the sculpture was the subject of the 2001 documentary The Sphere by filmmaker Percy Adlon. In August 2017, the work was installed at Liberty Park, close to the new World Trade Center aerial and the 9/11 Memorial.
The purpose of using the vacuum is to eliminate background signal and avoid intermolecular collision events, therefore, providing a long mean free path for the ions. The vacuum system, including the vacuum pumps and the vacuum manifold with its various interfaces, is often the heaviest part and consumes the most power in a mass spectrometer. In the case of TOF, if the length of drift region is decreased, the pressure inside region can be operated at higher value because the free collision region is still maintained for a short traveling distance of the ions. As a result, the vacuum system requires less power to run the system. For a trap-type mass analyzer, because the ions are trapped in the device for long periods and the accumulated trajectory length is much longer than the size of the mass analyzer, the size reduction of the mass analyzer may not directly affect the adequate operating pressure. Miniature rough-turbo pump configurations similar to lab-scale instruments have been developed to be compatible with MMS. For high-vacuum pumping, turbomolecular pumps are also upgraded. A Thermo Fisher Orbitrap used three turbo pumps in LC-MS modes to achieve a vacuum below 10−10 torr. Recently, a turbo pump from Creare, Inc.TM weighs only 500g and needs below 18 W power to run. The pump can provide the ultimate vacuum below 10−8 torr, which is much lower than the operating pressure necessary for a MMS.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.